OOIR: Observatory of International Research

Papers

(The median citation count of Translational Neurodegeneration is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes	923
Brain-derived neurotrophic factor in Alzheimer’s disease and its pharmaceutical potential	128
Excitotoxicity, calcium and mitochondria: a triad in synaptic neurodegeneration	123
The emerging roles of vacuolar-type ATPase-dependent Lysosomal acidification in neurodegenerative diseases	93
Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond	89
Peripheral clearance of brain-derived Aβ in Alzheimer's disease: pathophysiology and therapeutic perspectives	82
Advances in the development of new biomarkers for Alzheimer’s disease	75
COVID-19 and Alzheimer’s disease: how one crisis worsens the other	72
The role of pathological tau in synaptic dysfunction in Alzheimer’s diseases	66
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases	65
Mitochondria as a target for neuroprotection: role of methylene blue and photobiomodulation	57
Extensive frontal focused ultrasound mediated blood–brain barrier opening for the treatment of Alzheimer’s disease: a proof-of-concept study	48
The compensatory phenomenon of the functional connectome related to pathological biomarkers in individuals with subjective cognitive decline	48
Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson’s disease and their targeted therapeutic approaches: a comprehensive review	47
Alpha-synuclein seeding shows a wide heterogeneity in multiple system atrophy	44
TLR2 and TLR4 in Parkinson’s disease pathogenesis: the environment takes a toll on the gut	43
Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis	41
Gram-negative bacteria and their lipopolysaccharides in Alzheimer’s disease: pathologic roles and therapeutic implications	41
Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease	41
Tauroursodeoxycholic acid: a potential therapeutic tool in neurodegenerative diseases	40
The relationships of vitamin D, vitamin D receptor gene polymorphisms, and vitamin D supplementation with Parkinson’s disease	40
Multitasking guardian of mitochondrial quality: Parkin function and Parkinson’s disease	39
A new paradigm for diagnosis of neurodegenerative diseases: peripheral exosomes of brain origin	39
Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer’s disease	39
Increased prediction value of biomarker combinations for the conversion of mild cognitive impairment to Alzheimer’s dementia	38

Neurodegenerative diseases: a hotbed for splicing defects and the potential therapies	38
Upregulation of RIN3 induces endosomal dysfunction in Alzheimer’s disease	37
Advances in retina imaging as potential biomarkers for early diagnosis of Alzheimer’s disease	36
Transplantation of bone marrow mesenchymal stem cells improves cognitive deficits and alleviates neuropathology in animal models of Alzheimer’s disease: a meta-analytic review on potential mechanisms	34
SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease	34
CSF total and oligomeric α-Synuclein along with TNF-α as risk biomarkers for Parkinson’s disease: a study in LRRK2 mutation carriers	33
Maintaining the balance of TDP-43, mitochondria, and autophagy: a promising therapeutic strategy for neurodegenerative diseases	33
Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia	32
Nucleo–cytoplasmic transport defects and protein aggregates in neurodegeneration	31
Astrocyte dysfunction in Parkinson's disease: from the perspectives of transmitted α-synuclein and genetic modulation	31
A perspective on therapies for amyotrophic lateral sclerosis: can disease progression be curbed?	30
GCH1 variants contribute to the risk and earlier age-at-onset of Parkinson’s disease: a two-cohort case-control study	30
Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal	29
The effects of transcranial direct current stimulation on gait in patients with Parkinson’s disease: a systematic review	27
Impaired glymphatic function in the early stages of disease in a TDP-43 mouse model of amyotrophic lateral sclerosis	27
Mitochondrial links between brain aging and Alzheimer’s disease	26
Parkinson’s disease–associated VPS35 mutant reduces mitochondrial membrane potential and impairs PINK1/Parkin-mediated mitophagy	26
Extracellular vesicles, from the pathogenesis to the therapy of neurodegenerative diseases	26
The COVID-19 pandemic and Alzheimer’s disease: mutual risks and mechanisms	25
An old weapon with a new function: PIWI-interacting RNAs in neurodegenerative diseases	25
Does wild-type Cu/Zn-superoxide dismutase have pathogenic roles in amyotrophic lateral sclerosis?	25
Mechanisms of motor symptom improvement by long-term Tai Chi training in Parkinson’s disease patients	24
Circadian disruption and sleep disorders in neurodegeneration	24
Melatonin ameliorates tau-related pathology via the miR-504-3p and CDK5 axis in Alzheimer’s disease	23
Prodromal Parkinson's disease: hype or hope for disease-modification trials?	23
Targeting the overexpressed mitochondrial protein VDAC1 in a mouse model of Alzheimer’s disease protects against mitochondrial dysfunction and mitigates brain pathology	22
Targeting α-synuclein by PD03 AFFITOPE® and Anle138b rescues neurodegenerative pathology in a model of multiple system atrophy: clinical relevance	22
Ultrasensitive assays for detection of plasma tau and phosphorylated tau 181 in Alzheimer’s disease: a systematic review and meta-analysis	22
Exploring the regulatory roles of circular RNAs in Alzheimer’s disease	22
Defective lysosomal acidification: a new prognostic marker and therapeutic target for neurodegenerative diseases	22
LRRK2, GBA and their interaction in the regulation of autophagy: implications on therapeutics in Parkinson's disease	22
The emerging role of furin in neurodegenerative and neuropsychiatric diseases	22
Roles of physical exercise in neurodegeneration: reversal of epigenetic clock	22
Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriers	21
Neurofilament light and heterogeneity of disease progression in amyotrophic lateral sclerosis: development and validation of a prediction model to improve interventional trials	20
Effects of transcranial ultrasound stimulation pulsed at 40 Hz on Aβ plaques and brain rhythms in 5×FAD mice	20
Long-term hyperglycemia aggravates α-synuclein aggregation and dopaminergic neuronal loss in a Parkinson’s disease mouse model	20
Translational Neurodegeneration in the era of fast growing international brain research	20
New perspectives on cytoskeletal dysregulation and mitochondrial mislocalization in amyotrophic lateral sclerosis	20
Combined metabolic activators improve cognitive functions in Alzheimer’s disease patients: a randomised, double-blinded, placebo-controlled phase-II trial	19
Propagation of tau and α-synuclein in the brain: therapeutic potential of the glymphatic system	19
Ecto-GPR37: a potential biomarker for Parkinson’s disease	19
Potential use of corneal confocal microscopy in the diagnosis of Parkinson’s disease associated neuropathy	19
Optimization of cerebral organoids: a more qualified model for Alzheimer’s disease research	18
Associations of AT(N) biomarkers with neuropsychiatric symptoms in preclinical Alzheimer’s disease and cognitively unimpaired individuals	18
Language training for oral and written naming impairment in primary progressive aphasia: a review	18
Recommendations for the diagnosis and treatment of paroxysmal kinesigenic dyskinesia: an expert consensus in China	18
Redox dysregulation as a driver for DNA damage and its relationship to neurodegenerative diseases	18
Recent advances on the molecular mechanisms of exercise-induced improvements of cognitive dysfunction	17
LRRK2 mutant knock-in mouse models: therapeutic relevance in Parkinson's disease	17

Olfactory swab sampling optimization for α-synuclein aggregate detection in patients with Parkinson’s disease	17
Novel multivalent design of a monoclonal antibody improves binding strength to soluble aggregates of amyloid beta	16
The use of fibroblasts as a valuable strategy for studying mitochondrial impairment in neurological disorders	16
Acrolein scavenger dimercaprol offers neuroprotection in an animal model of Parkinson’s disease: implication of acrolein and TRPA1	16
Links between COVID-19 and Parkinson’s disease/Alzheimer’s disease: reciprocal impacts, medical care strategies and underlying mechanisms	15
Targeting neuroplasticity in patients with neurodegenerative diseases using brain stimulation techniques	15
Clinical and genetic characterization of a large cohort of patients with Wilson’s disease in China	15
TDP-43 dysregulation and neuromuscular junction disruption in amyotrophic lateral sclerosis	15
Dual role of brain-derived extracellular vesicles in dementia-related neurodegenerative disorders: cargo of disease spreading signals and diagnostic-therapeutic molecules	14
Parvalbumin neuroplasticity compensates for somatostatin impairment, maintaining cognitive function in Alzheimer’s disease	14
Disruption of orbitofrontal-hypothalamic projections in a murine ALS model and in human patients	14
Myelin repair in Alzheimer’s disease: a review of biological pathways and potential therapeutics	14
Early life adversity as a risk factor for cognitive impairment and Alzheimer’s disease	14
Aberrations of biochemical indicators in amyotrophic lateral sclerosis: a systematic review and meta-analysis	14
The Gold Coast criteria increases the diagnostic sensitivity for amyotrophic lateral sclerosis in a Chinese population	14
Downregulated miR-18b-5p triggers apoptosis by inhibition of calcium signaling and neuronal cell differentiation in transgenic SOD1 (G93A) mice and SOD1 (G17S and G86S) ALS patients	14
Defective mitophagy and the etiopathogenesis of Alzheimer’s disease	13
Intestine-derived α-synuclein initiates and aggravates pathogenesis of Parkinson’s disease in Drosophila	13
Parkinson’s disease and translational research	13
Pathophysiological significance of increased α-synuclein deposition in sympathetic nerves in Parkinson’s disease: a post-mortem observational study	12
Toward a biomarker panel measured in CNS-originating extracellular vesicles for improved differential diagnosis of Parkinson’s disease and multiple system atrophy	12
Genetic heterogeneity on sleep disorders in Parkinson’s disease: a systematic review and meta-analysis	12
EEG/ERP evidence of possible hyperexcitability in older adults with elevated beta-amyloid	12
Enhanced delivery of a low dose of aducanumab via FUS in 5×FAD mice, an AD model	12
Deciphering lipid dysregulation in ALS: from mechanisms to translational medicine	12
Paroxetine ameliorates prodromal emotional dysfunction and late-onset memory deficit in Alzheimer’s disease mice	12
Inflammation-induced PINCH expression leads to actin depolymerization and mitochondrial mislocalization in neurons	11
p85S6K sustains synaptic GluA1 to ameliorate cognitive deficits in Alzheimer’s disease	11
CRISPR/dCas9-Dnmt3a-mediated targeted DNA methylation of APP rescues brain pathology in a mouse model of Alzheimer’s disease	11
Neuropsychiatric symptoms are early indicators of an upcoming metabolic decline in Alzheimer’s disease	11
Stepping up to meet the challenge of freezing of gait in Parkinson’s disease	11
Pharmacological inhibition of asparaginyl endopeptidase by δ-secretase inhibitor 11 mitigates Alzheimer’s disease-related pathologies in a senescence-accelerated mouse model	11
Genetic spectrum and clinical features in a cohort of Chinese patients with autosomal recessive cerebellar ataxias	11
Employing nanoparticle tracking analysis of salivary neuronal exosomes for early detection of neurodegenerative diseases	10
A review of brain imaging biomarker genomics in Alzheimer’s disease: implementation and perspectives	10
Neurofilament light chain is increased in the parahippocampal cortex and associates with pathological hallmarks in Parkinson’s disease dementia	10
Inflammasome activation under high cholesterol load triggers a protective microglial phenotype while promoting neuronal pyroptosis	10
Disruption of the white matter structural network and its correlation with baseline progression rate in patients with sporadic amyotrophic lateral sclerosis	10
Predictability of polygenic risk score for progression to dementia and its interaction with APOE ε4 in mild cognitive impairment	10
Multi-mechanical waves against Alzheimer’s disease pathology: a systematic review	10
Differential seeding and propagating efficiency of α-synuclein strains generated in different conditions	10
Role of dopamine in the pathophysiology of Parkinson’s disease	10